{"filing":{"accession_number":"0001193125-26-429423","cik":"0001819133","ticker":"TNGX","company_name":"Tango Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"d151613d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613d8k.htm"},"events":[{"id":37412,"run_id":34485,"accession_number":"0001193125-26-429423","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Tango announced updated Phase 1/2 clinical trial results for vopimetostat in combination with RAS(ON) inhibitors, demonstrating an 82% objective response rate and 88% 9-month progression-free survival in pancreatic cancer patients, with plans to initiate a Phase 3 registrational trial in the first half of 2027. The company also disclosed a strategic reprioritization approved by the Board to focus on PRMT5-targeted therapies and deprioritize novel target discovery, accompanied by a planned approximately 14% workforce reduction.","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42116,"accession_number":"0001193125-26-429423","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tango announced updated Phase 1/2 clinical trial results for vopimetostat in combination with RAS(ON) inhibitors, showing an 82% objective response rate and 88% 9-month PFS in pancreatic cancer patients, with plans to initiate a Phase 3 registrational trial in 1H 2027. This is a material clinical milestone disclosure that would affect investor assessment of the company's pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure centers on clinical development progress and strategic direction rather than financial results, M\u0026A, or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:39:44.671030+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42117,"accession_number":"0001193125-26-429423","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 disclosure centers on promising Phase 1/2 clinical trial results for vopimetostat in combination with RAS(ON) inhibitors (82% ORR, 88% 9-month PFS in PDAC patients), regulatory plans to initiate a Phase 3 registrational trial in 1H 2027, and a strategic reprioritization approved by the Board on October 22, 2026 to focus on PRMT5-targeted therapies and deprioritize novel target discovery, including a planned ~14% workforce reduction. While clinical trial results and regulatory milestones are operational/strategic in nature, the workforce reduction component could also be classified as workforce_reduction. However, the primary focus of the disclosure is the clinical progress and strategic pivot, making operational_other the most appropriate classification. The event is material because it affects investor assessment of the company's pipeline, development strategy, and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:39:44.671030+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42116,"accession_number":"0001193125-26-429423","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tango announced updated Phase 1/2 clinical trial results for vopimetostat in combination with RAS(ON) inhibitors, showing an 82% objective response rate and 88% 9-month PFS in pancreatic cancer patients, with plans to initiate a Phase 3 registrational trial in 1H 2027. This is a material clinical milestone disclosure that would affect investor assessment of the company's pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure centers on clinical development progress and strategic direction rather than financial results, M\u0026A, or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:39:44.671030+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-10-23"},{"id":42117,"accession_number":"0001193125-26-429423","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 disclosure centers on promising Phase 1/2 clinical trial results for vopimetostat in combination with RAS(ON) inhibitors (82% ORR, 88% 9-month PFS in PDAC patients), regulatory plans to initiate a Phase 3 registrational trial in 1H 2027, and a strategic reprioritization approved by the Board on October 22, 2026 to focus on PRMT5-targeted therapies and deprioritize novel target discovery, including a planned ~14% workforce reduction. While clinical trial results and regulatory milestones are operational/strategic in nature, the workforce reduction component could also be classified as workforce_reduction. However, the primary focus of the disclosure is the clinical progress and strategic pivot, making operational_other the most appropriate classification. The event is material because it affects investor assessment of the company's pipeline, development strategy, and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:39:44.671030+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-10-23"}]}